New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
January 30, 2019 - The FDA announced the approval of Mylan’s Wixela™ Inhub™, a generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate/ salmeterol) inhalation powder.
Download PDF
Return to publications
